Hansoh Pharmaceutical Group (3692) H1 2025 earnings summary

Executive summary

• Revenue for the six months ended June 30, 2025, reached RMB7,434 million, up 14.3% year-over-year, driven by innovative drugs and collaborative products, which contributed 82.7% of total revenue.

• Net profit rose 15.0% year-over-year to RMB3,135 million, with basic EPS increasing 14.8% to RMB0.53.

• R&D expenditure increased 20.4% to RMB1,441 million, representing 19.4% of revenue.

• Interim dividend of HK$23.16 cents per share declared.

• Major R&D and regulatory milestones achieved, including new drug approvals, clinical trial advancements, and international licensing agreements.

Financial highlights

• Gross profit for the period was RMB6,773 million, with a gross margin of 91.1%.

• Operating cash flow was RMB3,605 million; cash and bank balances stood at RMB27,104 million as of June 30, 2025.

• Gearing ratio was 11.3%, up from 9.4% at year-end 2024.

• No material contingent liabilities or encumbrances on assets.

• R&D expenditure was RMB1,441 million, up 20.4% year-over-year, representing 19.4% of revenue.

Outlook and guidance

• Focus remains on innovation and internationalization, with continued investment in R&D and expansion in oncology, CNS, metabolism, and autoimmunity.

• Plans to accelerate core product pipeline development, strengthen external collaborations, and balance profitability with innovation investment for sustainable growth.